Fresenius Kabi, a global health care company based in Germany, hosted a topping off ceremony last week to celebrate the $100 million expansion of its pharmaceutical manufacturing campus in Wilson, North Carolina.
The topping off ceremony was a traditional celebration of construction projects upon the installation of the topmost structural member – in this case, signing celebrants’ names on the final huge steel I-beam at the growing pharmaceutical production center in Wilson.
The expansion will add at least 445 new jobs to the workforce of 100-plus at the Wilson County site by the time it’s completed in 2022, increasing the company’s production of affordable, generic medicines for use in hospitals and clinics.
The North Carolina Biotechnology Center provided technical support for the corporate expansion, in partnership with the North Carolina Department of Commerce and the Economic Development Partnership of North Carolina. Other partners included the North Carolina General Assembly, the North Carolina Community College System, Wilson County, the city of Wilson, and the Wilson Economic Development Council.
Fresenius Kabi, with global headquarters in Bad Homburg, Germany, specializes in medicines and technologies for infusion, transfusion and clinical nutrition used to help critically and chronically ill patients.
The company broke ground in September 2017 on a $250 million expansion at its pharmaceutical manufacturing site in Melrose Park, Ill. In total, the company employs more than 3,000 people in the U.S., including at its U.S. headquarters in Lake Zurich, Illinois.
This article by Wyatt Corbett, writer for the North Carolina Biotechnology Center, originally appeared on the on the NC Biotech Center website here. NC Biotech Center website. The North Carolina Biotechnology Center is a private, nonprofit corporation supported by the North Carolina General Assembly. The center’s loans, grants, programs and activities develop strengths that yield transformational partnerships and life science jobs statewide.